WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Amir Khan's £11.5m luxury wedding venue finally hosts its first marriage: Bride arrives on horse
Zhang Yufei Wins Women's 100m Butterfly at Hangzhou Asiad
China Claims Women's Team Title at Asian Table Tennis Championships
Enjoying Breathtaking Winter Landscapes
Helping Design China's First Large Passenger Aircraft
Young Chinese Woman Wins Fame by Making Traditional Handicrafts from Everyday Materials
Renters now pay an extra £5,993 a year in rent and energy bills compared to a decade ago
California congressman urges closer consultation with tribes on offshore wind
'He pees ice cubes!' Ice cool Kroos key to Germany's hopes